17th April 2018
Isomerase Therapeutics expands their senior management team with the addition of Karen Reddy as their new Financial Controller. She brings 15 years of financial experience, across various industries, including the biotech, property and media industries.
Karen joins Isomerase after a number of years as Financial Controller at Mission Therapeutics Ltd., a VC-backed Cambridge biotech company. Previous experience has included time as Financial Controller at the Whitfield Group and 6 years in various financial roles at BSkyB.
Dr Matt Gregory, the CEO of Isomerase stated “We are delighted to have Karen join the expanding team here at Isomerase Therapeutics. She is an excellent addition to our management team, and we look forward to her help with the continued growth and success of Isomerase.”